疾患早期発見への

Mirxes Holding Company Limited (the “Company”; Stock code: 2629) marked a significant milestone today as its shares debuted on the Main Board of The Stock Exchange of Hong Kong Limited (HKEX), closing its first day of trade as a new biotech unicorn with a market capitalisation of HK$8.29 billion (US$1.06 billon).

Mirxes, a leading RNA technology company specializing in early cancer detection and precision medicine, today announced a US$40 million structured financing transaction with CBC Group’s R-Bridge Healthcare Fund (“R-Bridge”). This partnership will provide critical support for Mirxes’ ambitious growth and expansion into key global markets.

In a First-In-Singapore collaboration, leading RNA technology company Mirxes and PULSE TCM, a renowned provider of traditional Chinese Medicine (TCM) services, today launched the holistic “East Meets West” Community Health Screening Pilot at Bukit Gombak. Witnessed by Ms Low Yen Ling, Senior Minister of State, Ministry of Culture, Community and Youth, Ministry of Trade and Industry, Mayor of South West District and Grassroots Adviser to Bukit Gombak Grassroots Organisations, this pilot represents a novel approach towards integrating contemporary Western precision diagnostic technology with Eastern TCM wisdom, aimed at creating an integrated approach to preventive and personalised healthcare for a Healthier Singapore.

The National University Hospital (NUH) and Mirxes are proud to announce the official opening of the NUH DMOC@Biopolis, one of Singapore’s first publicprivate partnership centres for specialty molecular testing. The NUH DMOC@Biopolis is an extension of NUH’s Diagnostic Molecular Oncology Centre (DMOC) that co-locates and integrates with Mirxes’ clinical laboratory, M Diagnostics at Biopolis. The Centre was inaugurated today by Deputy Prime Minister, Coordinating Minister for Economic Policies, and Chairman of the National Research Foundation (NRF), Mr Heng Swee Keat.

Mirxes Corporation USA, the wholly owned subsidiary of Mirxes Pte Ltd, a Singapore-headquartered RNA technology company that is making diagnostic solutions for the early detection of diseases accessible on a global scale, announced today that its flagship product GASTROClearTM, a PCR-based in vitro diagnostic test for early detection of gastric (stomach) cancer, has been granted Breakthrough Device Designation by the U.S.